Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Peter Greven is a privately held, family-owned German chemical company whose healthcare relevance is primarily through the manufacture of pharmaceutical excipients rather than the development of therapeutics. The company is a leading producer of oleochemical additives based on renewable raw materials and operates within the broader Peter Greven Group, which also includes occupational skin care businesses. In life sciences, Peter Greven supplies vegetable-based stearates and related excipients for pharmaceutical, nutraceutical, food, and cosmetic applications, with the LIGAMED product line positioned for pharmaceutical use. Its Venlo, Netherlands site is dedicated to high-quality pharmaceutical excipient manufacturing, and the company emphasizes GMP-aligned production, pharmacopeial compliance, and quality certifications. Peter Greven does not appear to be a biotech or drug-development company with a clinical pipeline; instead, it is best understood as a commercial specialty ingredients and excipients supplier serving pharmaceutical manufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Peter Greven.